Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial

Keyphrases

• Perfusion 100%
• Insulin Sensitivity 100%
• Dapagliflozin 100%
• Type 2 Diabetic Patients 75%
• Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i) 75%
• Positron Emission Tomography/computed Tomography (PET/CT) 75%
• Glucose Uptake 50%
• Hyperinsulinemic-euglycemic Clamp 50%
• 18F-fluorocholine PET/CT 50%
• Whole-body 25%
• Treatment Initiation 25%
• Single Center 25%
• Placebo 25%
• Primary Prevention 25%
• Afterload Reduction 25%
• Percutaneous Coronary Intervention 25%
• Plasma Glucose 25%
• Non-diabetic 25%
• Skeletal muscle 25%
• Heart Failure 25%
• Myocardial Perfusion 25%
• Beneficial Effects 25%
• Risk Factors 25%
• Coronary Vessels 25%
• Left Ventricular Function 25%
• Adipose Tissue 25%
• Standard of Care 25%
• Cardiac Function 25%
• Trial Registration 25%
• Previous History 25%
• Placebo-controlled Study 25%
• Cardiovascular Effects 25%
• Cardiovascular Risk Profile 25%
• Decreased Risk 25%
• History of Myocardial Infarction 25%
• CT Images 25%
• Glycemic Control 25%
• Stable Coronary Artery Disease 25%
• CT Studies 25%
• Visceral Fat 25%
• Glycated Hemoglobin A1c 25%
• Myocardial Layers 25%
• Myocardial Function 25%
• Cardiovascular Outcomes 25%
• Insulin Requirement 25%
• High Cardiovascular Risk 25%
• EudraCT 25%
• Suboptimal Glycemic Control 25%
• Fuel Consumption 25%
• Cardiovascular Protection 25%
• Glucose-lowering Drugs 25%
• Whole Tissue 25%
• Subcutaneous Fat 25%
• Antihyperglycemic 25%
• Substrate Availability 25%
• Myocardial Glucose Uptake 25%
• Myocardial Blood Flow 25%
• Pericardial Fat 25%
• Urinary Glucose Excretion 25%
• Tissue-specific Insulin Resistance 25%
• Wall Condition 25%
• Microbiota Alteration 25%
• Liver-kidney 25%
• 13N-ammonia Positron Emission Tomography 25%

Medicine and Dentistry

• Insulin Sensitivity 100%
• Dapagliflozin 100%
• Patient with Type 2 Diabetes 75%
• Glucose Uptake 75%
• Positron Emission Tomography-Computed Tomography 75%
• Sodium Glucose Cotransporter 2 Inhibitor 75%
• Cardiovascular System 75%
• Sodium-Glucose Cotransporter 2 Inhibitors 75%
• Fluorodeoxyglucose 50%
• Heart Function 50%
• Glycemic Control 50%
• Glucose 50%
• Percutaneous Coronary Intervention 25%
• Myocardial Infarction 25%
• Placebo 25%
• Afterload 25%
• Insulin 25%
• Arm 25%
• Coronary Artery Disease 25%
• Heart Muscle Perfusion 25%
• Insulin Resistance 25%
• Urinary System 25%
• Adipose Tissue 25%
• Cardiovascular Risk 25%
• Coronary Vessel 25%
• Glycated Hemoglobin 25%
• Heart Left Ventricle Function 25%
• Congestive Heart Failure 25%
• Primary Prevention 25%
• Visceral Fat 25%
• Placebo-Controlled Study 25%
• Hemoglobin A1c 25%
• Heart Muscle Blood Flow 25%
• Ammonia N 13 25%
• Skeletal Muscle 25%
• Microflora 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Insulin 100%
• Dapagliflozin 100%
• Glucose 100%
• Sodium Glucose Cotransporter 2 Inhibitor 60%
• sodium glucose cotransporter-2 inhibitors 60%
• Maturity Onset Diabetes of the Young 60%
• Fluorodeoxyglucose 40%
• Polyethylene Terephthalate 40%
• Heart Infarction 20%
• Placebo 20%
• Microflora 20%
• Coronary Artery Disease 20%
• Glycosylated Hemoglobin 20%
• Cardiovascular Risk 20%
• Insulin Resistance 20%
• Congestive Heart Failure 20%
• Placebo-Controlled Study 20%
• Hemoglobin A1c 20%
• Ammonia N 13 20%